全文获取类型
收费全文 | 214635篇 |
免费 | 3172篇 |
国内免费 | 73篇 |
专业分类
耳鼻咽喉 | 1519篇 |
儿科学 | 7826篇 |
妇产科学 | 3861篇 |
基础医学 | 22614篇 |
口腔科学 | 1837篇 |
临床医学 | 15840篇 |
内科学 | 40120篇 |
皮肤病学 | 1682篇 |
神经病学 | 20097篇 |
特种医学 | 10047篇 |
外国民族医学 | 31篇 |
外科学 | 33727篇 |
综合类 | 2401篇 |
一般理论 | 9篇 |
预防医学 | 20777篇 |
眼科学 | 3363篇 |
药学 | 12123篇 |
中国医学 | 703篇 |
肿瘤学 | 19303篇 |
出版年
2023年 | 217篇 |
2022年 | 256篇 |
2021年 | 652篇 |
2020年 | 400篇 |
2019年 | 709篇 |
2018年 | 22932篇 |
2017年 | 18074篇 |
2016年 | 20183篇 |
2015年 | 1846篇 |
2014年 | 1840篇 |
2013年 | 2378篇 |
2012年 | 9594篇 |
2011年 | 23494篇 |
2010年 | 20024篇 |
2009年 | 12535篇 |
2008年 | 21733篇 |
2007年 | 23954篇 |
2006年 | 2798篇 |
2005年 | 4576篇 |
2004年 | 5776篇 |
2003年 | 6505篇 |
2002年 | 4535篇 |
2001年 | 1423篇 |
2000年 | 1588篇 |
1999年 | 1146篇 |
1998年 | 450篇 |
1997年 | 386篇 |
1996年 | 259篇 |
1995年 | 260篇 |
1994年 | 227篇 |
1993年 | 174篇 |
1992年 | 579篇 |
1991年 | 570篇 |
1990年 | 612篇 |
1989年 | 524篇 |
1988年 | 460篇 |
1987年 | 430篇 |
1986年 | 378篇 |
1985年 | 356篇 |
1984年 | 251篇 |
1983年 | 209篇 |
1982年 | 144篇 |
1980年 | 127篇 |
1979年 | 168篇 |
1974年 | 144篇 |
1973年 | 120篇 |
1971年 | 119篇 |
1970年 | 130篇 |
1969年 | 160篇 |
1968年 | 133篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
31.
Peter Angelos 《World journal of surgery》2009,33(4):609-611
32.
Kentaroh Miyoshi Minoru Naito Tsuyoshi Ueno Shinji Hato Hideo Ino 《General thoracic and cardiovascular surgery》2009,57(11):629-632
A benign esophageal leiomyoma with abnormally increased fluorine-18-fluorodeoxyglucose uptake on positron emission tomography
(PET) was resected thoracoscopically. The tumor, of which the maximum standardized uptake value of the lesion was 4.7, was
well defined and 38 mm in diameter. Neither mitotic activity nor degeneration was found histologically; and immunoreactivity
for CD34, CD117, MIB-1, and glucose transporter-1 was negative immunohistochemically. A diagnosis of gastrointestinal stromal
tumor was ruled out by an oncogenic kinase gene mutation study. This case cautions against PET-dependent evaluation for malignant
potential of esophageal submucosal tumors. 相似文献
33.
34.
Simon Bell Andrew J McLachlan Parisa Aslani Paula Whitehead Timothy F Chen 《Australia and New Zealand Health Policy》2005,2(1):29
The objective of this systematic review was to evaluate the impact of pharmacist delivered community-based services to optimise the use of medications for mental illness. Twenty-two controlled (randomised and non-randomised) studies of pharmacists' interventions in community and residential aged care settings identified in international scientific literature were included for review. Papers were assessed for study design, service recipient, country of origin, intervention type, number of participating pharmacists, methodological quality and outcome measurement. Three studies showed that pharmacists' medication counselling and treatment monitoring can improve adherence to antidepressant medications among those commencing treatment when calculated using an intention-to-treat analysis. Four trials demonstrated that pharmacist conducted medication reviews may reduce the number of potentially inappropriate medications prescribed to those at high risk of medication misadventure. The results of this review provide some evidence that pharmacists can contribute to optimising the use of medications for mental illness in the community setting. However, more well designed studies are needed to assess the impact of pharmacists as members of community mental health teams and as providers of comprehensive medicines information to people with schizophrenia and bipolar disorder 相似文献
35.
Statutory reimbursement agencies as well as private insurers throughout member states of the Organization for Economic Cooperation and Development (OECD) reimburse the cost of medicines on the basis of criteria that include robust clinical evidence, budget impact analysis, and incremental cost effectiveness. The Centers for Medicare and Medicaid Services (CMS) in the US are no exception to this rule and are, in principle, seeking to maximize benefit for their Medicare enrollees, whilst ensuring reasonable drug outlays for the small number of drugs that they reimburse. This paper provides a retrospective analysis of the way two functionally equivalent drugs are treated for reimbursement purposes by the CMS; the period under consideration was 2001–3. The two drugs, epoetin-α and darbepoetin-α, are used for the treatment of anemia in renal failure and in patients receiving chemotherapy. By reviewing the publicly available pharmacological and clinical data of epoetin-α and darbepoetin-α, the paper confirms the two drugs’ functional equivalence, despite their structural differences. The implications of dose conversion ratios and costs to Medicare are subsequently explored. It is argued that the issue of dose equivalence between epoetin-α and darbepoetin-α has significant implications for patients, practitioners, and payors. A payor’s perspective is adopted in this respect, whereby clinical evidence and pricing data are used simultaneously. Based on the clinical evidence, a dose conversion ratio for epoetin-α:darbepoetin-α is established, which achieves a comparable clinical effect for the two drugs and this is set to be <254IU:1μg. The incremental costs to Medicare are calculated subsequently. The Average Wholesale Price and the Outpatient Prospective Payment System rule that Medicare uses to reimburse providers are used and suggest that treatment of cancer patients with chemotherapy-related anemia with epoetin-α would save Medicare an estimated $US600 million each year. Patients would also benefit significantly in terms of lower co-payments for epoetin-α. The evidence is supportive of the decision made by the CMS to reimburse the two drugs at the rate reflecting the achievement of comparable clinical effects and therefore reducing the pass-through payments for darbepoetin-α to zero for the 2002–3 fiscal year. 相似文献
36.
37.
38.
The aim of this study was to investigate the role of plasma glucagon levels on the blood glucose response to intravenous insulin administered continuously or in a pulsatile manner. Six type I diabetic patients proven to have no residual insulin secretion were investigated. Endogenous glucagon secretion was inhibited by a continuous intravenous infusion of somatostatin (100 micrograms/h) and replaced by exogenous infusions of the hormone at three different rates (7.5, 4.5, and 2.5 micrograms/h), resulting in three different plasma glucagon steady-state levels (i.e., approximately equal to 200, approximately equal to 130, and approximately equal to 75 pg/ml, respectively). Each subject, in random order and on different days, was infused intravenously with regular human insulin either continuously (0.17 mU X kg-1 X min-1) or with the same amount of insulin infused in a pulsatile manner (0.85 mU X kg-1 X min-1 during 2 min followed by 8 min during which no insulin was infused). At plasma glucagon levels approximately equal to 200 pg/ml, blood glucose rose from approximately 10 to approximately 13 mM without any difference between the two modalities of insulin infusion. For plasma glucagon levels approximately equal to 130 pg/ml, plasma glucose remained steady throughout the experiments, but during the last 40 min, plasma glucose levels were significantly lower when insulin was administered intermittently. This greater blood glucose-lowering effect of pulsatile insulin occurred earlier and was more pronounced for plasma glucagon levels averaging 75 pg/ml. We conclude that the greater hypoglycemic effect of insulin administered intravenously in a pulsatile manner in type I diabetics critically depends on plasma glucagon circulating levels. 相似文献
39.
J T Christenson A Broomè L Norgren B Eklof 《The Journal of cardiovascular surgery》1986,27(2):131-135
The late results--up to six years--after axillo-femoral bypass reconstruction are reported for 85 patients with leg ischaemia who were regarded as poor-risk patients for aortic bypass surgery, or who had aortic graft infection. Velour-Dacron grafts and expanded polytetrafluoroethylene (PTFE, Gore-Tex)--grafts have been used. The cumulative patency rate (life table) six years after graft implantation was 64% (PTFE-grafts) and 58% (Velour-Dacron grafts). The corresponding cumulative limb salvage rate six years after graft implantation was 88% when PTFE grafts were used and 77% when Velour-Dacron grafts were used. Our results demonstrate that axillo-femoral reconstruction is a useful procedure with a good patency rate 6 years after implantation. This procedure should be considered when dealing with poor risk patients with severe leg ischaemia. 相似文献
40.